|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Low tumor NLRX1 expression was identified as an independent indicator for HCC prognosis (recurrence: hazard ratio [HR] 1.87, 95% confidence interval [CI] 1.26-2.76, overall survival [OS] 2.26, 95% CI 1.44-3.56).
|
29482578 |
2018 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
High NOD2 and low NLRX1 expression in tumor tissue was associated with short MST (P = 0.012 and 0.014, respectively).
|
28960882 |
2017 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Recent publications have suggested a role for the NLR, NLRX1, in acting as a tumor suppressor.
|
27105514 |
2016 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Two recent studies demonstrate that NLRX1 functions as an intrinsic tumor suppressor in intestinal epithelial cells (IEC), by regulating their responses to proliferative signals following intestinal injury.
|
27452288 |
2016 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Application of anti-interleukin 6 receptor (IL6R) antibody therapy reduced tumor burden, increased survival, and reduced STAT3 activation in Nlrx1(-/-)Apc(min/+) mice.
|
26971998 |
2016 |
|
Colitis
|
0.040 |
Biomarker
|
disease |
BEFREE |
Cell-specificity studies using cre-lox mice demonstrate that the loss of NLRX1 in intestinal epithelial cells (IEC) recapitulate the increased sensitivity to DSS colitis observed in whole body <i>Nlrx1</i><sup>-/-</sup> mice.
|
29535731 |
2018 |
|
Colitis
|
0.040 |
Biomarker
|
disease |
BEFREE |
Metabolic effects of NLRX1 deficiency are observed in a CD4-specific knockout of NLRX1 within a <i>Citrobacter rodentium</i> model of colitis.
|
28159898 |
2017 |
|
Colitis
|
0.040 |
Biomarker
|
disease |
BEFREE |
This work shows that NLRX1 serves as a tumor suppressor in colitis-associated cancer (CAC) and sporadic colon cancer by keeping key tumor promoting pathways in check.
|
26971998 |
2016 |
|
Colitis
|
0.040 |
Biomarker
|
disease |
BEFREE |
Our findings showed that the regulatory function of PUA on colitis is NLRX1 dependent.
|
26714018 |
2015 |
|
Inflammatory Bowel Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
NX-13 is a small molecule therapeutic designed to target and activate NLRX1 to induce immunometabolic changes resulting in lower inflammation and therapeutic responses in inflammatory bowel disease (IBD).
|
31650868 |
2019 |
|
Inflammatory Bowel Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
NX-13 is a promising oral, gut-restricted NLRX1 agonist for treating IBD.
|
31694910 |
2019 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
These evidences suggest an essential role of NLRX1 in maintaining the crosstalk of mitochondrial metabolism and lysosomal function to regulate invasion and metastasis capability of breast cancer cells.
|
30802640 |
2019 |
|
Inflammatory Bowel Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
In conclusion, NLRX1 is an immunoregulatory molecule and a candidate modulator of the interplay between mucosal inflammation, metabolism, and the gut microbiome during IBD.
|
29535731 |
2018 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
These findings demonstrate that NLRX1 functions as a negative regulator to inactivate the Beclin 1-UVRAG complex, which regulates invasion and autophagy during GAS infection.
|
30488027 |
2018 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Transwell assays were conducted to evaluate the effect of NLRX1 on cell invasion, and flow cytometry was used to assess apoptosis.
|
29482578 |
2018 |
|
Liver carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Low tumor NLRX1 expression was identified as an independent indicator for HCC prognosis (recurrence: hazard ratio [HR] 1.87, 95% confidence interval [CI] 1.26-2.76, overall survival [OS] 2.26, 95% CI 1.44-3.56).
|
29482578 |
2018 |
|
Liver carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
NOD2 and NLRX1 expression levels are potential prognostic markers in HCC following hepatectomy.
|
28960882 |
2017 |
|
Malignant tumor of colon
|
0.020 |
Biomarker
|
disease |
BEFREE |
These data implicate anti-IL6R as a potential personalized therapy for colon cancers with reduced NLRX1.
|
26971998 |
2016 |
|
Malignant tumor of colon
|
0.020 |
Biomarker
|
disease |
BEFREE |
Colon Cancer in the Land of NOD: NLRX1 as an Intrinsic Tumor Suppressor.
|
27452288 |
2016 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Together, these data show that NLRX1 suppresses tumorigenesis and reveals new genetic pathways involved in the pathobiology of histiocytic sarcoma.
|
27105514 |
2016 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
NLRX1 attenuated Apc(min/+) colon tumorigenesis, cellular proliferation, NF-κB, MAPK, STAT3 activation, and IL-6 levels.
|
26971998 |
2016 |
|
Colon Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Colon Cancer in the Land of NOD: NLRX1 as an Intrinsic Tumor Suppressor.
|
27452288 |
2016 |
|
Colon Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
As an important clinical correlate, human colon cancer samples expressed lower levels of NLRX1 than healthy controls in multiple patient cohorts.
|
26971998 |
2016 |
|
Autoimmune Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
In summary, our findings highlight the importance of NLRX1 in controlling the early stages of CNS inflammation and preventing the onset of spontaneous autoimmunity.
|
31525189 |
2019 |
|
Malignant neoplasm of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Expression analyses of clinical breast cancer samples and meta-analysis of multiple public databases revealed that NLRX1 expression is significantly increased in basal-like and metastatic breast carcinoma as compared to non-basal-like and primary breast cancer.
|
30802640 |
2019 |